Clover Health Investments Corp (CLOV) Q3 2026 Earnings Call Highlights: First Full-Year GAAP …

This article first appeared on GuruFocus.

Release Date: November 04, 2026

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Clover Health Investments Corp (NASDAQ:CLOV) expects to deliver its first full year of GAAP net income profitability in 2026, with GAAP net income of $25-35 million.

• Membership grew nearly 50% year over year to approximately 157,000 members, driving total revenue up 57% to $2.3 billion.

• Adjusted EBITDA more than doubled to $97 million, and consolidated gross profit increased by $161 million to $442 million.

• The flagship PPO plan achieved a 5-star rating for payment year 2028, and 100% of members are in plans rated at least 4.5 stars, providing flexibility to invest in benefits.

• Clover Assistant coverage is accelerating and tracking ahead of last year, which is a key leading indicator for cohort maturation and future earnings growth.

• The company has a strong balance sheet with $513 million in cash and no debt, and cash flow from operations totaled $203 million through September.

Negative Points

• Clover Health Investments Corp (NASDAQ:CLOV) expects a seasonal adjusted EBITDA loss in Q4 due to normal medical cost seasonality and higher SG&A from planned AEP investments.

• Outpatient utilization is elevated year over year, which could pressure medical costs.

• The company faces litigation risk with the government’s appeal pending regarding the Stars program, which could impact payments if the government prevails.

• New member growth may be a near-term drag on earnings in 2027 as new cohorts are dilutive initially.

• The company did not provide formal guidance for 2027 or 2028, citing uncertainty around AEP results and investment plans.

• A significant portion of membership is early in its lifecycle, with 28% in year one and 21% in year two, which may limit near-term profitability.

Q & A Highlights

Q: With Braven exiting New Jersey and Devoted entering, how are AEP dynamics playing out, and did you underwrite the switching opportunity from Braven in your 2027 bids? A: CFO Clay Thornton said the company anticipated planned exits in New Jersey and had a good read on where those members would go, factoring that into 2027 plan designs. Braven’s exit involves roughly low 40,000 MA lives, while large nationals are again retreating from $0 PPOs. Early AEP returns show things “playing out quite well,” with strong growth and an “incredibly strong” competitive position.

Q: How does Clover Assistant coverage trending ahead of last year relate to the two-thirds figure cited in the presentation, and does it imply greater-than-normal cohort maturation upside? A: CFO Clay Thornton said the two-thirds number is the average CA coverage observed over recent years, while the year-over-year comparison reflects October tracking, which is ahead of last year and trending toward that goal. He said CA coverage is the number one leading indicator for cohort maturation, and higher coverage drives stronger economics, with tracking ahead across all cohorts and geographies.

Q: Are there geographic differences in cohort performance, such as stronger economics in the more mature New Jersey market versus Georgia? A: CFO Clay Thornton said cohort performance correlates strongly with Clover Assistant coverage. Because Clover has operated longest in New Jersey, its CA network is deepest there and coverage is highest, so driving more membership in New Jersey yields stronger cohort economics.

Q: With 4.5 stars in 2027 and five stars in 2028, does that change your thinking on expanding into smaller markets like the Carolinas, Texas or Pennsylvania, or is there still room in New Jersey and Georgia? A: CFO Clay Thornton noted 4.5 stars in 2027 and five stars in 2028 carry the same payment dynamics in both years. He said there remains significant room to run in New Jersey and Georgia, which stay the near-term focus, and declined to comment on 2028 growth strategy until next year.

Q: With 98% of members on one large PPO contract, does splitting into additional H contracts become more attractive given stars and litigation-driven volatility? A: CFO Clay Thornton said new H contracts would be part of any future market expansion assessment. The large PPO contract is predominantly concentrated in Georgia and New Jersey, where Clover has a strong CA network and operations to navigate stars, and he said new contracts “could make a lot of sense” as expansion is evaluated.

Q: How much of the incremental 2027 benefit from cohort maturation and stars do you expect to retain in earnings versus reinvest in the business? A: CFO Clay Thornton declined to give a specific figure, saying the company is in planning mode and assessing a series of investments for 2027, with details to come when guidance is issued.

Q: With the government’s appeal pending, what is the range of outcomes for 2027, and could CMS change payments if the government prevails after the year begins? A: CEO Andrew Toy said Clover is thinking through all scenarios but feels very good about its positioning on the appeal and believes the original court decision was well-decided. He said the company would address any adverse outcome if and when it happens, given the many possible scenarios.

Q: How do you view the Stars program today, and what changes would you prioritize to make it more predictable? A: CEO Andrew Toy said rewarding plans for quality makes sense, but many current measures don’t truly measure quality. He advocated moving to a more data-driven, granular, personalized approach that measures quality on an individualized basis rather than using large, non-personalized denominators.

Q: What gives you confidence you can deliver earnings expansion while onboarding a larger member cohort, and could growth absorb some of the cohort maturation benefit? A: CFO Clay Thornton said this is the third consecutive year of significant growth, so Clover understands how to absorb it, staff appropriately and engage new members in Clover Assistant. He acknowledged new members could be a near-term drag on 2027 earnings, but said the model is built to move them along the cohort maturation curve.

Q: Can you frame the MLR improvement from maturation versus first-year members, and give insight into the acuity and quality of incoming AEP members? A: CFO Clay Thornton pointed to prior cohort maturation stats of roughly $70 PMPM improvement from year one to year two and $85 from year two to year three, noting about 21% of members move into year three and 28% into year two in 2027. He declined to size new member acuity three weeks into AEP, saying early results are strong and more detail will come after AEP.

Q: Given the five-star plan, would you expect to increase marketing next year, including during OEP and SEP, after pulling back intra-year in 2026? A: CFO Clay Thornton said Clover is purely focused on AEP right now, about three weeks in with very strong results. The company will revisit OEP and SEP strategy once it has a better sense of 1/1/2027 membership.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.